Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly

被引：0
|
作者：
Ignacio Bernabéu
Carmen Fajardo
Mónica Marazuela
Fernando Cordido
Eva María Venegas
Pedro de Pablos-Velasco
Gonzalo Piedrola Maroto
María Pilar Olvera
Isabel Pavón de Paz
Davide Carvalho
Carme Romero
Guillermo De la Cruz
Cristina Álvarez Escolá
机构：
[1] Hospital Clínico Universitario Santiago de Compostela,Endocrinology and Nutrition Department
[2] Hospital Universitario de La Ribera,Endocrinology and Nutrition Department
[3] Hospital Universitario La Princesa,Endocrinology and Nutrition Department
[4] Universidad Autónoma Madrid,Faculty of Health Sciences and INIBIC, University of A Coruña, and Endocrinology and Nutrition Department
[5] Instituto Princesa,Endocrinology and Nutrition Department
[6] Complejo Hospitalario Universitario de A Coruña,Endocrinology and Nutrition Department
[7] Hospital Universitario Virgen del Rocío,Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário São João
[8] University of Las Palmas de Gran Canaria. Spain,Endocrinology and Nutrition Department
[9] Endocrinology and Nutrition Departament Hospital Universitario Virgen de las Nieves,undefined
[10] Endocrinology and Nutrition Departament,undefined
[11] Hospital Universitario Nuestra Señora de Candelaria,undefined
[12] Endocrinology and Nutrition Departament,undefined
[13] Hospital Universitario de Getafe,undefined
[14] Faculty of Medicine,undefined
[15] i3S,undefined
[16] Universidade do Porto,undefined
[17] Adknoma Health Research S.L.,undefined
[18] Ipsen Pharma,undefined
[19] Hospital Universitario La Paz,undefined
来源：
Endocrine | 2020年 / 70卷
关键词：
Acromegaly; Lanreotide; Insulin-like growth factor 1; Somatostatin; Growth hormone;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：575 / 583
页数：8
相关论文
共 50 条
  • [41] A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly
    Fleseriu, M.
    Zhang, Z.
    Hanman, K.
    Haria, K.
    Houchard, A.
    Khawaja, S.
    Ribeiro-Oliveira, A., Jr.
    Gadelha, M.
    PITUITARY, 2023, 26 (01) : 9 - 41
  • [42] Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism
    Shimatsu, Akira
    Teramoto, Akira
    Hizuka, Naomi
    Kitai, Kazuo
    Ramis, Joaquim
    Chihara, Kazuo
    ENDOCRINE JOURNAL, 2013, 60 (05) : 651 - 663
  • [43] Efficacy of lanreotide Autogel® administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg:: a phase III trial
    Lucas, T.
    Astorga, R.
    CLINICAL ENDOCRINOLOGY, 2006, 65 (03) : 320 - 326
  • [44] Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly
    Yasemin Tutuncu
    Dilek Berker
    Serhat Isik
    Ufuk Ozuguz
    Gulhan Akbaba
    Ferit Kerim Kucukler
    Yusuf Aydin
    Serdar Guler
    Pituitary, 2012, 15 : 398 - 404
  • [45] Efficacy of a slow-release formulation of lanreotide (Autogel® 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR):: an open, multicentre longitudinal study
    Ronchi, C. L.
    Boschetti, M.
    Uberti, E. C. Degli
    Mariotti, S.
    Grottoli, S.
    Loli, P.
    Lombardi, G.
    Tamburrano, G.
    Arvigo, M.
    Angeletti, G.
    Boscani, P. F.
    Beck-Peccoz, P.
    Arosio, M.
    CLINICAL ENDOCRINOLOGY, 2007, 67 (04) : 512 - 519
  • [46] Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly
    G. Lombardi
    F. Minuto
    G. Tamburrano
    M. R. Ambrosio
    G. Arnaldi
    M. Arosio
    V. Chiarini
    R. Cozzi
    S. Grottoli
    F. Mantero
    F. Bogazzi
    M. Terzolo
    P. Tita
    P. F. Boscani
    A. Colao
    Journal of Endocrinological Investigation, 2009, 32 : 202 - 209
  • [47] COST EFFECTIVENESS OF ORAL BISPHOSPHONATES ADMINISTERED ON EXTENDED DOSING INTERVALS
    Moore, E.
    Devine, J. W.
    Trice, S.
    Mistry, H. H.
    Potyk, R.
    Nwokeji, E. D.
    VALUE IN HEALTH, 2009, 12 (03) : A163 - A163
  • [48] Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly
    Tutuncu, Yasemin
    Berker, Dilek
    Isik, Serhat
    Ozuguz, Ufuk
    Akbaba, Gulhan
    Kucukler, Ferit Kerim
    Aydin, Yusuf
    Guler, Serdar
    PITUITARY, 2012, 15 (03) : 398 - 404
  • [49] Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly
    Lombardi, G.
    Minuto, F.
    Tamburrano, G.
    Ambrosio, M. R.
    Arnaldi, G.
    Arosio, M.
    Chiarini, V.
    Cozzi, R.
    Grottoli, S.
    Mantero, F.
    Bogazzi, F.
    Terzolo, M.
    Tita, P.
    Boscani, P. F.
    Colao, A.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2009, 32 (03): : 202 - 209
  • [50] A multicentric randomized phase III study to evaluate the equivalence between lanreotide PR 60 mg vs lanreotide Autogel 120 mg in well-differentiated neuroendocrine tumours (NETs)
    Bajetta, E
    Procopio, G
    Catena, L
    Ferrari, L
    Ricci, S
    Lacobelli, S
    Carteni, G
    De Braud, F
    Loli, P
    Vezzadini, P
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 351S - 351S
12345